Overview

Multiple myeloma is a blood cancer that forms in plasma cells, a type of white blood cell. Healthy plasma cells make proteins called antibodies. Antibodies work with other parts of the immune system to help protect the body from germs.

In multiple myeloma, cancerous plasma cells build up in bone marrow. The bone marrow is the soft, spongy tissue inside most bones where blood cells are made.

Myeloma cells make proteins that are not typical. These proteins are called monoclonal proteins, also known as M proteins. These proteins can build up and damage organs, such as the kidneys.

Multiple myeloma is generally preceded by a condition called monoclonal gammopathy of undetermined significance (MGUS). In MGUS, the amount of monoclonal protein is low, and the plasma cell condition doesn't cause myeloma-related organ damage. Most people with MGUS don't develop multiple myeloma.

Multiple myeloma, leukemia and lymphoma are blood cancers, but they start in different tissues or cells. Multiple myeloma starts in plasma cells. Leukemia happens when white blood cells that are not usual grow in excess and don't work as they typically do in blood-forming tissues such as bone marrow. Lymphoma starts in immune cells called lymphocytes.

Treatment can help control multiple myeloma, reduce complications and ease symptoms. It may help people live longer.

Types

Active multiple myeloma

Active multiple myeloma is diagnosed when testing shows a plasma cell condition and at least one myeloma-defining event. These events include myeloma-related organ damage or certain test findings that show a high risk of organ damage. Active multiple myeloma generally needs treatment.

Smoldering multiple myeloma

In smoldering multiple myeloma, blood or bone marrow test results show a plasma cell condition, but there is no myeloma-defining event. The condition hasn't caused organ damage or bone lesions. Most people are monitored instead of being treated right away. People with high-risk smoldering multiple myeloma may be offered treatment.

Call your preferred Mayo Clinic location:

Symptoms

Some people with multiple myeloma have no symptoms at first. Symptoms may include:

  • Bone pain, especially in the back, chest or hips.
  • Weak or easily broken bones.
  • Tiredness.
  • Frequent infections.
  • Shortness of breath.

Multiple myeloma can cause a high level of calcium in the blood, called hypercalcemia. Symptoms of high calcium can include:

  • Nausea.
  • Constipation.
  • Loss of appetite.
  • Confusion or trouble thinking clearly.
  • Weakness.
  • Feeling very thirsty.
  • Needing to urinate often.

When to see a doctor

Make an appointment with a doctor or other healthcare professional if you have any of these symptoms or other symptoms that worry you.

Get Mayo Clinic cancer expertise delivered to your inbox.

Subscribe for free and receive an in-depth guide to coping with cancer, plus helpful information on how to get a second opinion. You can unsubscribe at any time. Click here for an email preview.

I would like to learn more about

We use the data you provide to deliver you the content you requested. To provide you with the most relevant and helpful information, we may combine your email and website data with other information we have about you. If you are a Mayo Clinic patient, we will only use your protected health information as outlined in our Notice of Privacy Practices. You may opt out of email communications at any time by clicking on the unsubscribe link in the email.

Causes

It's not clear what causes multiple myeloma.

The disease develops through several changes in plasma cells and in the bone marrow. These changes allow myeloma cells to survive and build up in the bone marrow.

Multiple myeloma involves genetic changes in cancer cells. Having a close family member with multiple myeloma or a related plasma cell condition also raises the risk of developing the disease. But the disease doesn't follow one simple inherited pattern.

Risk factors

Many factors can raise the risk of multiple myeloma.

  • Age. The risk of multiple myeloma goes up with age. The median age at diagnosis is about 65.
  • Sex at birth. Men are more likely to develop the disease than are women.
  • Race. In the United States, Black people are more likely to develop multiple myeloma than white people.
  • Family history of multiple myeloma. Having a sibling or parent with multiple myeloma raises the risk of having the disease.
  • MGUS. Having MGUS raises the risk of multiple myeloma. But most people with MGUS do not get multiple myeloma.

Complications

Complications of multiple myeloma include:

  • Infections. Multiple myeloma can make it harder for the immune system to fight bacterial and viral infections.
  • Bone issues. Multiple myeloma can cause bone pain, thinning bones and broken bones.
  • Kidney issues. Multiple myeloma may damage the kidneys and may lead to kidney failure.
  • Anemia and other blood cell conditions. Myeloma cells interfere with blood cell production in the bone marrow. This can cause a low red blood cell count, called anemia.

Prevention

No lifestyle or environmental change is known to prevent multiple myeloma. Because no direct cause has been found, a diagnosis doesn't mean you did anything to cause it.

Aug. 22, 2026

Living with multiple myeloma?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

daisy249
Who do I see for porphyria?

33 Replies Thu, Aug 20, 2026

cdurbin
What are most common side effects when starting HU (Hydroxyurea)?

230 Replies Sat, Aug 15, 2026

See more discussions
  1. Multiple myeloma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445. Accessed Aug. 3, 2026.
  2. Kumar SK, et al. Multiple myeloma, version 5.2026, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0001.
  3. Treatment of multiple myeloma: ASCO Living Guideline, version 2026.1.2. American Society of Clinical Oncology. https://ascopubs.org/guidelines/treatment-multiple-myeloma-asco-living-guideline. Accessed Aug. 3, 2026.
  4. Hicks LK, et al. Treatment of multiple myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. Journal of Clinical Oncology. 2026; doi:10.1200/JCO-25-02587.
  5. Plasma cell neoplasms (including multiple myeloma) treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq. Accessed Aug. 3, 2026.
  6. Cancer stat facts: Myeloma. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed Aug. 3, 2026.
  7. Stem cell transplants in cancer treatment. National Cancer Institute. Accessed Aug. 7, 2026.
  8. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2024; doi:10.1002/ajh.27422.
  9. Malard F, et al. Multiple myeloma. Nature Reviews Disease Primers. 2024; doi:10.1038/s41572-024-00529-7.
  10. Nanni C, et al. EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. European Journal of Nuclear Medicine and Molecular Imaging. 2024; doi:10.1007/s00259-024-06858-9.
  11. Zanwar S, et al. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders. Leukemia. 2025; doi:10.1038/s41375-025-02654-y. PMID: 40702148.
  12. Avet-Loiseau H, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. Journal of Clinical Oncology. 2025; doi:10.1200/JCO-24-01893.
  13. Alzahrani K, et al. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology. 2024; doi:10.1111/bjh.19384.
  14. Dimopoulos MA, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. New England Journal of Medicine. 2025; doi:10.1056/NEJMoa2409029.
  15. Amitai I, et al. Role of autologous transplant in newly diagnosed multiple myeloma patients treated with novel triplets: A systematic review and meta-analysis. Acta Haematologica. 2025; doi:10.1159/000540232.
  16. Costa LJ, et al. International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025; doi:10.1038/s41375-024-02482-6.
  17. Lin Y, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma. Lancet Oncology. 2024; doi:10.1016/S1470-2045(24)00094-9.
  18. Rodriguez-Otero P, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncology. 2024; doi:10.1016/S1470-2045(24)00043-3.
  19. Ludwig H, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network. Lancet Oncology. 2023; doi:10.1016/S1470-2045(23)00159-6.
  20. Peipert JD, et al. Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma. JAMA Network Open. 2024; doi:10.1001/jamanetworkopen.2024.3854.
  21. Dimopoulos MA, et al. Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group. Lancet Oncology. 2023; doi:10.1016/S1470-2045(23)00223-1.
  22. Carlson LE, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. Journal of Clinical Oncology. 2023; doi:10.1200/JCO.23.00857.
  23. Bower JE, et al. Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. Journal of Clinical Oncology. 2024; doi:10.1200/JCO.24.00541.
  24. Bone marrow. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bone-marrow. Accessed Aug. 5, 2026.
  25. What is cancer? National Cancer Institute. https://www.cancer.gov. Accessed Aug. 5, 2026.
  26. Plasma cell neoplasms (including multiple myeloma) treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq. Accessed Aug. 5, 2026.
  27. Signs and symptoms of multiple myeloma. American Cancer Society. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/signs-symptoms.html. Accessed Aug. 5, 2026.
  28. Medical review (expert opinion). Mayo Clinic. August 10, 2026.